TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth

Androgen receptor (AR) inhibitors represent the mainstay of prostate cancer treatment. In a genome-wide CRISPR-Cas9 screen using LNCaP prostate cancer cells, loss of co-repressor TLE3 conferred resistance to AR antagonists apalutamide and enzalutamide. Genes differentially expressed upon TLE3 loss s...

Descripción completa

Detalles Bibliográficos
Autores principales: Palit, Sander AL, Vis, Daniel, Stelloo, Suzan, Lieftink, Cor, Prekovic, Stefan, Bekers, Elise, Hofland, Ingrid, Šuštić, Tonći, Wolters, Liesanne, Beijersbergen, Roderick, Bergman, Andries M, Győrffy, Balázs, Wessels, Lodewyk FA, Zwart, Wilbert, van der Heijden, Michiel S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2019
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968917/
https://www.ncbi.nlm.nih.gov/pubmed/31855178
http://dx.doi.org/10.7554/eLife.47430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968917/
https://www.ncbi.nlm.nih.gov/pubmed/31855178
http://dx.doi.org/10.7554/eLife.47430

Ejemplares similares